The ROE as of December 2025 (TTM) for Neuren Pharmaceuticals Limited (NURPF) is 43.38%

According to Neuren Pharmaceuticals Limited’s latest financial reports and current stock price. The company's current ROE is 43.38%. This represents a change of 76.37% compared to the average of 24.60% of the last 4 quarters.

Neuren Pharmaceuticals Limited (NURPF) Historical ROE (quarterly & annually)

How has NURPF ROE performed in the past?

The mean historical ROE of Neuren Pharmaceuticals Limited over the last ten years is -36.76%. The current 43.38% ROE has changed -218.01% with respect to the historical average. Over the past ten years (40 quarters), NURPF's ROE was at its highest in in the December 2023 quarter at 53.25%. The ROE was at its lowest in in the June 2017 quarter at -361.71%.

Neuren Pharmaceuticals Limited (NURPF) ROE by Quarter and Year

Discovering the peaks and valleys of Neuren Pharmaceuticals Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Neuren Pharmaceuticals Limited (NURPF) Average ROE

How has NURPF ROE performed in the past?

The current ROE of Neuren Pharmaceuticals Limited (NURPF) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Neuren Pharmaceuticals Limited (NURPF) ROE vs. Peers

How is NURPF’s ROE compared to its peers?

Neuren Pharmaceuticals Limited’s ROE is greater than Molecular Partners AG (-50.31%), greater than MediciNova, Inc. (-23.12%), greater than Anebulo Pharmaceuticals, Inc. (-67.78%), less than Champions Oncology, Inc. (87.06%), greater than Cyteir Therapeutics, Inc. (-26.35%), greater than Aerovate Therapeutics, Inc. (-49.03%), greater than Enliven Therapeutics, Inc. (-29.15%), greater than MoonLake Immunotherapeutics (-41.61%), greater than Structure Therapeutics Inc. (-21.34%), greater than Compass Therapeutics, Inc. (-48.90%), greater than Ventyx Biosciences, Inc. (-48.11%), less than Keros Therapeutics, Inc. (9.51%), greater than Crinetics Pharmaceuticals, Inc. (-35.09%), greater than Cerevel Therapeutics Holdings, Inc. (-72.44%), greater than Vaxcyte, Inc. (-21.08%), greater than Assembly Biosciences, Inc. (-149.01%), greater than NextCure, Inc. (-107.57%), greater than Nuvation Bio Inc. (-54.99%), greater than Graphite Bio, Inc. (-25.63%), greater than Instil Bio, Inc. (-54.32%), greater than PMV Pharmaceuticals, Inc. (-47.95%), greater than Olema Pharmaceuticals, Inc. (-41.51%), greater than Enochian Biosciences, Inc. (-385.07%), greater than Scholar Rock Holding Corporation (-121.95%), greater than Passage Bio, Inc. (-103.87%),

Build a custom stock screener for Neuren Pharmaceuticals Limited (NURPF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neuren Pharmaceuticals Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Neuren Pharmaceuticals Limited (NURPF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Neuren Pharmaceuticals Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.